NewAmsterdam Pharma Company N.V.
NAMS
$36.40
-$0.07-0.19%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -165.72M | -187.36M | -241.60M | -198.92M | -229.40M |
| Total Depreciation and Amortization | 176.00K | 150.00K | 113.00K | 75.00K | 61.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 62.86M | 58.96M | 115.60M | 60.04M | 61.98M |
| Change in Net Operating Assets | -21.44M | -12.19M | -32.67M | -15.36M | -21.27M |
| Cash from Operations | -124.12M | -140.43M | -158.56M | -154.16M | -188.63M |
| Capital Expenditure | -182.00K | -303.00K | -672.00K | -672.00K | -606.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -218.35M | -59.31M | -62.18M | -- | -- |
| Cash from Investing | -218.54M | -59.61M | -62.85M | -672.00K | -606.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 468.22M | 469.46M | 661.04M | 204.40M | 204.53M |
| Repurchase of Common Stock | 0.00 | 0.00 | -989.00K | -989.00K | -989.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.61M | -1.61M | -540.00K | -515.00K | -515.00K |
| Cash from Financing | 466.61M | 467.85M | 659.51M | 202.90M | 203.02M |
| Foreign Exchange rate Adjustments | 9.20M | -535.00K | -6.80M | 6.36M | 215.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 133.16M | 267.27M | 431.29M | 54.42M | 14.00M |